The Recombinant Proteins Market size was estimated USD 2.4 billion in 2022 and is expected to reach USD 5.8 billion by 2030 at a CAGR of 11.9%during the forecast period of 2023-2030.
Recombinant proteins are created by the use of recombinant DNA (rDNA) technology, which requires the combination of at least two DNA sequences that are not normally found together in nature. These rDNA libraries, as well as the proteins that come from them, are subsequently evaluated for their potential application as disease pathway inhibitors, replacement therapies, or other anti-disease medicines. The genetic level of recombinant protein production begins with the separation and cloning of the desired protein's coding sequence into an expression plasmid vector.
DRIVERS
Biologics patent expiration
The global market is expanding in tandem with the life science and biopharmaceutical sectors, which are major end users of recombinant protein products. The increased number of end users has prompted various corporations to introduce new products and invest in the worldwide market. Blockbuster mAbs are currently expiring in the pharmaceutical sector. To address this challenge, major global pharmaceutical companies are implementing a variety of tactics to boost research operations. These policies are likely to boost the number of drug development initiatives aimed at developing therapeutic antibodies, particularly mAbs, which will open up new potential for the global market.
RESTRAIN
Recombinant protein prices are falling
Price erosion is characterized as a large number of businesses entering a niche market and offering similar items with no uniqueness, flooding the market with less inventive and competitively priced products. During price erosion, the price of such products in the specific market is observed to consistently fall, which consequently slows market growth. New technological advancements in the field of recombinant protein manufacturing process have changed the older trend, resulting in higher yield and lower cost of finished products, allowing such proteins to be produced on an industrial scale and allowing small players to compete on price without innovation, limiting market growth.
OPPORTUNITY
Increased emphasis on customized medicine and protein therapies
Personalized medicine requires the integration of numerous biotechnologies, such as cell and gene treatments, recombinant proteins, and vaccines, because they play an important role in therapy personalization. Personalized medicine has made its way into standard clinical practices and is changing how many diseases are discovered, classified, and treated. It has become a primary focus of research in the healthcare industry. Recombinant protein treatments, including as hormones, vaccines, monoclonal antibodies, blood factors, and therapeutic enzymes, have also grown in popularity in recent years. Recombinant protein treatments have received widespread attention for their ability to treat a wide range of ailments, and their demand has grown dramatically in recent years as the prevalence of chronic diseases has increased. Recombinant proteins are renowned as highly effective treatments that are free of off-target negative effects, and they develop faster than small molecules.
CHALLENGE
Protein aggregation into inclusion bodies impedes the synthesis of soluble recombinant proteins with functional biological functions.
One of the species of choice for producing recombinant proteins is Escherichia coli. Its function as a cell factory is well known, and it has become the most common expression platform. High-level recombinant protein production in Escherichia coli frequently results in the agglomeration of the produced protein molecules into inclusion bodies. Retrieving active recombinant protein from inclusion bodies is a time-consuming and labor-intensive operation. The creation of inclusion bodies in bacterial hosts poses a significant obstacle for large-scale bioactive protein recovery. The extraction of bioactive protein from inclusion bodies is a time-consuming procedure with modest recombinant protein yields. Such difficulties in the production of recombinant proteins have a detrimental impact on the market.
Russia's invasion of Ukraine is expected to affect millions of people worldwide, not only in the Eastern European country, as medicine developers may face delays in clinical trials in Kyiv and elsewhere. One biotech company in particular raised the possibility of geopolitical conflicts as a source of concern. Because 10 of the 19 trial sites are in Ukraine, Karuna Therapeutics has warned that timeframes for its second phase 3 research in schizophrenia, dubbed EMERGENT-3, are questionable. Karuna stated in a further statement made late Thursday evening that the company's top concern is the safety of its clinical trial partners and patients.
By Product
Product
Cytokines & Growth Factors
Interferons (IFNs)
Interleukins (ILs)
Others
Antibodies
Immune Checkpoint Proteins
Virus Antigens
Enzymes
Kinases
Metabolic enzymes
Others
Recombinant Regulatory Protein
Hormones
Others
Production Services
In 2022, product segment is expected to held the highest market share of 67.5% during the forecast period. This segment is expanding as a result of extensive product utilization in fields such as cancer, HIV/AIDS, COVID-19, immunology, and neurology, among others. In addition, growth factors and cytokines are important in cancer research.
By Host Cell
Mammalian Systems
Insect Cells
Yeast & Fungi
Bacterial Cells
Others
In 2022, mammalian systems segment is expected to held the highest market share of 43.3% during the forecast period. Mammalian protein expression is growing more popular as the proteomics and biologics markets grow. Protein expression systems are straightforward to include into high throughput systems for effective biologics and proteomics investigations since they are widely available. Furthermore, the emphasis on creating biopharmaceutical goods has expanded as a result of variables such as rising cancer incidence and prevalence, as well as increased research and development (R&D) efforts, which are driving industry expansion.
By Application
Drug Discovery & Development
Therapeutics
Biologics
Vaccines
Cell & Gene Therapies
Others
Research
Others
In 2022, the therapeutics segment is expected to dominate the market growth of 35.4% during the forecast period the prevalence of diseases such as metabolic disorders, cancer, genetic disorders, and immunological diseases rises, so will the demand for protein-based treatments. Furthermore, cancer is one of the major causes of death worldwide, and the World Health Organization (WHO) anticipates a large increase in cancer incidence in the future years.
By End User
Pharma & Biotechnology Companies
Academic & Research Institutes
Diagnostic Laboratories
Others
.png)
In 2022, pharma & biotechnology companies segment is expected to dominate the market growth of 40.1% during the forecast period owing to trend toward biologics and biosimilars has resulted in a cascade of multi-million-dollar investments in R&D by bio-manufacturers for expanding product pipelines, developing new technologies, and advancing bioprocessing techniques. Rising demand, increased competition among players, and a variety of applications by end users have all contributed to developments in recombinant protein products.
North America held a significant market share growing with a CAGR of 35.7% in 2022 due to increased research spending, the availability of healthcare infrastructure, and the existence of a number of industry participants. Furthermore, because recombinant proteins are one of the tested treatments for such problems, the chronic diseases that are expanding throughout the region are creating a significant need for recombinant protein therapies.
Asia Pacific is witness to expand fastest CAGR rate during the forecast period owing to the growth in public and commercial financing for recombinant protein research and development, favorable government laws, and the increased prevalence of target diseases with an aging population. Furthermore, the advancement of sophisticated methodologies in proteomic and genomic research is pushing the region's expansion.
REGIONAL COVERAGE
North America
US
Canada
Mexico
Europe
Eastern Europe
Poland
Romania
Hungary
Turkey
Rest of Eastern Europe
Western Europe
Germany
France
UK
Italy
Spain
Netherlands
Switzerland
Austria
Rest of Western Europe
Asia Pacific
China
India
Japan
South Korea
Vietnam
Singapore
Australia
Rest of Asia Pacific
Middle East & Africa
Middle East
UAE
Egypt
Saudi Arabia
Qatar
Rest of Middle East
Africa
Nigeria
South Africa
Rest of Africa
Latin America
Brazil
Argentina
Colombia
Rest of Latin America
The major key players are Thermo Fisher Scientific, Inc., Miltenyi Biotech, Sino Biological Inc., Merck KGaA, Abcam plc, Biolegend, Bio-Rad Laboratories, Inc., GenScript Biotech Corporation, Enzo Life Sciences, Inc., Shenandoah Biotechnology Inc., BPS Bioscience, Inc., and Others.
In December 2022, Shenandoah Biotechnology Inc. has expanded its CTGrade array of growth factors and cytokines for cell and gene treatments prepared in accordance with cGMP criteria. CTGrade cytokines include IL-3, IL-2, IL-7, IL-6, IL-10, IL-21, IL-15, and FLT-3 ligand, as well as the extra proteins required in development to maximize cell proliferation and function for innovative cell and gene treatments.
In January 2022, Thermo Fisher Scientific Inc. stated that it will complete the acquisition of PeproTech in December 2021 for a total of about US $1.85 billion. This acquisition will allow Thermo Fisher to provide significant benefits to their customers via a unified offering.
|
Report Attributes |
Details |
|
Market Size in 2022 |
US$ 2.4 billion |
|
Market Size by 2030 |
US$ 5.8 billion |
|
CAGR |
CAGR of 11.9% From 2023 to 2030 |
|
Base Year |
2022 |
|
Forecast Period |
2023-2030 |
|
Historical Data |
2019-2021 |
|
Report Scope & Coverage |
Market Size, Segments Analysis, Competitive Landscape, Regional Analysis, DROC & SWOT Analysis, Forecast Outlook |
|
Key Segments |
By Product & Services (Product, Production Services), By Host Cell (Mammalian Systems, Insect Cells, Yeast & Fungi, Bacterial Cells, Others), By Application (Drug Discovery & Development, Therapeutics, Research, Others), By End User (Pharma & Biotechnology Companies, Academic & Research Institutes, Diagnostic Laboratories, Others) |
|
Regional Analysis/Coverage |
North America (US, Canada, Mexico), Europe (Eastern Europe [Poland, Romania, Hungary, Turkey, Rest of Eastern Europe] Western Europe] Germany, France, UK, Italy, Spain, Netherlands, Switzerland, Austria, Rest of Western Europe]), Asia Pacific (China, India, Japan, South Korea, Vietnam, Singapore, Australia, Rest of Asia Pacific), Middle East & Africa (Middle East [UAE, Egypt, Saudi Arabia, Qatar, Rest of Middle East], Africa [Nigeria, South Africa, Rest of Africa], Latin America (Brazil, Argentina, Colombia Rest of Latin America) |
|
Company Profiles |
Texas Instruments (US), Skyworks Solutions, Inc. (US), Analog Devices (US), Broadcom Inc. (US), and Infineon Technologies (Germany), ON Semiconductor (U.S.), Murata Manufacturing Company Ltd (Japan), STMicroelectronics N.V. (Switzerland), NXP Semiconductors N.V. (the Netherlands), Vicor Corporation (U.S.) |
|
Market Opportunities |
•Increased emphasis on customized medicine and protein therapies |
|
Market Challenges |
•Protein aggregation into inclusion bodies impedes the synthesis of soluble recombinant proteins with functional biological functions. |
The recombinant proteins market is expected to grow at 11.9%CAGR from 2023 to 2030.
According to our analysis, the recombinant proteins market is anticipated to reach USD 5.8 billion By 2030.
Recombinant proteins market size was valued at USD 2.4 billion in 2022.
increased research activities for medication development and precision medicine, rising use of biologics and biosimilars, and increasing spending in research & development activities.
The products segment dominated the recombinant proteins market with a share of 67.5% in 2022.
TABLE OF CONTENT
1. Introduction
1.1 Market Definition
1.2 Scope
1.3 Research Assumptions
2. Research Methodology
3. Market Dynamics
3.1 Drivers
3.2 Restraints
3.3 Opportunities
3.4 Challenges
4. Impact Analysis
4.1 Impact of the Ukraine- Russia war
4.2 Impact of ongoing Recession
4.2.1 Introduction
4.2.2 Impact on major economies
4.2.2.1 US
4.2.2.2 Canada
4.2.2.3 Germany
4.2.2.4 France
4.2.2.5 United Kingdom
4.2.2.6 China
4.2.2.7 Japan
4.2.2.8 South Korea
4.2.2.9 Rest of the World
5. Value Chain Analysis
6. Porter’s 5 forces model
7. PEST Analysis
8. Recombinant Proteins Market Segmentation, by Product & Services
8.1 Product
8.1.1 Cytokines & Growth Factors
8.1.1.1 Interferons (IFNs)
8.1.1.2 Interleukins (ILs)
8.1.1.3 Others
8.1.2 Antibodies
8.1.3 Immune Checkpoint Proteins
8.1.4 Virus Antigens
8.1.5 Enzymes
8.1.5.1 Kinases
8.1.5.2 Metabolic enzymes
8.1.5.3 Others
8.1.6 Recombinant Regulatory Protein
8.1.7 Hormones
8.1.8 Others
8.2 Production Services
9. Recombinant Proteins Market Segmentation, by Host Cell
9.1 Mammalian Systems
9.2 Insect Cells
9.3 Yeast & Fungi
9.4 Bacterial Cells
9.5 Other
10. Recombinant Proteins Market Segmentation, by Application
10.1 Drug Discovery & Development
10.2 Therapeutics
10.2.1 Biologics
10.2.2 Vaccines
10.2.3 Cell & Gene Therapies
10.2.4 Others
10.3 Research
10.4 Others
11. Recombinant Proteins Market Segmentation, by End User
11.1 Pharma & Biotechnology Companies
11.2 Academic & Research Institutes
11.3 Diagnostic Laboratories
11.4 Others
12. Regional Analysis
12.1 Introduction
12.2 North America
12.2.1 North America Recombinant Proteins Market by Country
12.2.2North America Recombinant Proteins Market by Product & Services
12.2.3 North America Recombinant Proteins Market by Host Cell
12.2.4 North America Recombinant Proteins Market by Application
12.2.5 North America Recombinant Proteins Market by End User
12.2.6 USA
12.2.6.1 USA Recombinant Proteins Market by Product & Services
12.2.6.2 USA Recombinant Proteins Market by Host Cell
12.2.6.3 USA Recombinant Proteins Market by Application
12.2.6.4 USA Recombinant Proteins Market by End User
12.2.7 Canada
12.2.7.1 Canada Recombinant Proteins Market by Product & Services
12.2.7.2 Canada Recombinant Proteins Market by Host Cell
12.2.7.3 Canada Recombinant Proteins Market by Application
12.2.7.4 Canada Recombinant Proteins Market by End User
12.2.8 Mexico
12.2.8.1 Mexico Recombinant Proteins Market by Product & Services
12.2.8.2 Mexico Recombinant Proteins Market by Host Cell
12.2.8.3 Mexico Recombinant Proteins Market by Application
12.2.8.4 Mexico Recombinant Proteins Market by End User
12.3 Europe
12.3.1 Eastern Europe
12.3.1.1 Eastern Europe Recombinant Proteins Market by Country
12.3.1.2 Eastern Europe Recombinant Proteins Market by Product & Services
12.3.1.3 Eastern Europe Recombinant Proteins Market by Host Cell
12.3.1.4 Eastern Europe Recombinant Proteins Market by Application
12.3.1.5 Eastern Europe Recombinant Proteins Market by End User
12.3.1.6 Poland
12.3.1.6.1 Poland Recombinant Proteins Market by Product & Services
12.3.1.6.2 Poland Recombinant Proteins Market by Host Cell
12.3.1.6.3 Poland Recombinant Proteins Market by Application
12.3.1.6.4 Poland Recombinant Proteins Market by End User
12.3.1.7 Romania
12.3.1.7.1 Romania Recombinant Proteins Market by Product & Services
12.3.1.7.2 Romania Recombinant Proteins Market by Host Cell
12.3.1.7.3 Romania Recombinant Proteins Market by Application
12.3.1.7.4 Romania Recombinant Proteins Market by End User
12.3.1.8 Hungary
12.3.1.8.1 Hungary Recombinant Proteins Market by Product & Services
12.3.1.8.2 Hungary Recombinant Proteins Market by Host Cell
12.3.1.8.3 Hungary Recombinant Proteins Market by Application
12.3.1.8.4 Hungary Recombinant Proteins Market by End User
12.3.1.9 Turkey
12.3.1.9.1 Turkey Recombinant Proteins Market by Product & Services
12.3.1.9.2 Turkey Recombinant Proteins Market by Host Cell
12.3.1.9.3 Turkey Recombinant Proteins Market by Application
12.3.1.9.4 Turkey Recombinant Proteins Market by End User
12.3.1.10 Rest of Eastern Europe
12.3.1.10.1 Rest of Eastern Europe Recombinant Proteins Market by Product & Services
12.3.1.10.2 Rest of Eastern Europe Recombinant Proteins Market by Host Cell
12.3.1.10.3 Rest of Eastern Europe Recombinant Proteins Market by Application
12.3.1.10.4 Rest of Eastern Europe Recombinant Proteins Market by End User
12.3.2 Western Europe
12.3.2.1 Western Europe Recombinant Proteins Market by Country
12.3.2.2 Western Europe Recombinant Proteins Market by Product & Services
12.3.2.3 Western Europe Recombinant Proteins Market by Host Cell
12.3.2.4 Western Europe Recombinant Proteins Market by Application
12.3.2.5 Western Europe Recombinant Proteins Market by End User
12.3.2.6 Germany
12.3.2.6.1 Germany Recombinant Proteins Market by Product & Services
12.3.2.6.2 Germany Recombinant Proteins Market by Host Cell
12.3.2.6.3 Germany Recombinant Proteins Market by Application
12.3.2.6.4 Germany Recombinant Proteins Market by End User
12.3.2.7 France
12.3.2.7.1 France Recombinant Proteins Market by Product & Services
12.3.2.7.2 France Recombinant Proteins Market by Host Cell
12.3.2.7.3 France Recombinant Proteins Market by Application
12.3.2.7.4 France Recombinant Proteins Market by End User
12.3.2.8 UK
12.3.2.8.1 UK Recombinant Proteins Market by Product & Services
12.3.2.8.2 UK Recombinant Proteins Market by Host Cell
12.3.2.8.3 UK Recombinant Proteins Market by Application
12.3.2.8.4 UK Recombinant Proteins Market by End User
12.3.2.9 Italy
12.3.2.9.1 Italy Recombinant Proteins Market by Product & Services
12.3.2.9.2 Italy Recombinant Proteins Market by Host Cell
12.3.2.9.3 Italy Recombinant Proteins Market by Application
12.3.2.9.4 Italy Recombinant Proteins Market by End User
12.3.2.10 Spain
12.3.2.10.1 Spain Recombinant Proteins Market by Product & Services
12.3.2.10.2 Spain Recombinant Proteins Market by Host Cell
12.3.2.10.3 Spain Recombinant Proteins Market by Application
12.3.2.10.4 Spain Recombinant Proteins Market by End User
12.3.2.11 Netherlands
12.3.2.11.1 Netherlands Recombinant Proteins Market by Product & Services
12.3.2.11.2 Netherlands Recombinant Proteins Market by Host Cell
12.3.2.11.3 Netherlands Recombinant Proteins Market by Application
12.3.2.11.4 Netherlands Recombinant Proteins Market by End User
12.3.2.12 Switzerland
12.3.2.12.1 Switzerland Recombinant Proteins Market by Product & Services
12.3.2.12.2 Switzerland Recombinant Proteins Market by Host Cell
12.3.2.12.3 Switzerland Recombinant Proteins Market by Application
12.3.2.12.4 Switzerland Recombinant Proteins Market by End User
12.3.2.13 Austria
12.3.2.13.1 Austria Recombinant Proteins Market by Product & Services
12.3.2.13.2 Austria Recombinant Proteins Market by Host Cell
12.3.2.13.3 Austria Recombinant Proteins Market by Application
12.3.2.13.4 Austria Recombinant Proteins Market by End User
12.3.2.14 Rest of Western Europe
12.3.2.14.1 Rest of Western Europe Recombinant Proteins Market by Product & Services
12.3.2.14.2 Rest of Western Europe Recombinant Proteins Market by Host Cell
12.3.2.14.3 Rest of Western Europe Recombinant Proteins Market by Application
12.3.2.14.4 Rest of Western Europe Recombinant Proteins Market by End User
12.4 Asia-Pacific
12.4.1 Asia Pacific Recombinant Proteins Market by Country
12.4.2 Asia Pacific Recombinant Proteins Market by Product & Services
12.4.3 Asia Pacific Recombinant Proteins Market by Host Cell
12.4.4 Asia Pacific Recombinant Proteins Market by Application
12.4.5 Asia Pacific Recombinant Proteins Market by End User
12.4.6 China
12.4.6.1 China Recombinant Proteins Market by Product & Services
12.4.6.2 China Recombinant Proteins Market by Host Cell
12.4.6.3 China Recombinant Proteins Market by Application
12.4.6.4 China Recombinant Proteins Market by End User
12.4.7 India
12.4.7.1 India Recombinant Proteins Market by Product & Services
12.4.7.2 India Recombinant Proteins Market by Host Cell
12.4.7.3 India Recombinant Proteins Market by Application
12.4.7.4 India Recombinant Proteins Market by End User
12.4.8 Japan
12.4.8.1 Japan Recombinant Proteins Market by Product & Services
12.4.8.2 Japan Recombinant Proteins Market by Host Cell
12.4.8.3 Japan Recombinant Proteins Market by Application
12.4.8.4 Japan Recombinant Proteins Market by End User
12.4.9 South Korea
12.4.9.1 South Korea Recombinant Proteins Market by Product & Services
12.4.9.2 South Korea Recombinant Proteins Market by Host Cell
12.4.9.3 South Korea Recombinant Proteins Market by Application
12.4.9.4 South Korea Recombinant Proteins Market by End User
12.4.10 Vietnam
12.4.10.1 Vietnam Recombinant Proteins Market by Product & Services
12.4.10.2 Vietnam Recombinant Proteins Market by Host Cell
12.4.10.3 Vietnam Recombinant Proteins Market by Application
12.4.10.4 Vietnam Recombinant Proteins Market by End User
12.4.11 Singapore
12.4.11.1 Singapore Recombinant Proteins Market by Product & Services
12.4.11.2 Singapore Recombinant Proteins Market by Host Cell
12.4.11.3 Singapore Recombinant Proteins Market by Application
12.4.11.4 Singapore Recombinant Proteins Market by End User
12.4.12 Australia
12.4.12.1 Australia Recombinant Proteins Market by Product & Services
12.4.12.2 Australia Recombinant Proteins Market by Host Cell
12.4.12.3 Australia Recombinant Proteins Market by Application
12.4.12.4 Australia Recombinant Proteins Market by End User
12.4.13 Rest of Asia-Pacific
12.4.13.1 Rest of Asia-Pacific Recombinant Proteins Market by Product & Services
12.4.13.2 Rest of Asia-Pacific Recombinant Proteins Market by Host Cell
12.4.13.3 Rest of Asia-Pacific Recombinant Proteins Market by Application
12.4.13.4 Rest of Asia-Pacific Recombinant Proteins Market by End User
12.5 Middle East & Africa
12.5.1 Middle East
12.5.1.1 Middle East Recombinant Proteins Market by country
12.5.1.2 Middle East Recombinant Proteins Market by Product & Services
12.5.1.3 Middle East Recombinant Proteins Market by Host Cell
12.5.1.4 Middle East Recombinant Proteins Market by Application
12.5.1.5 Middle East Recombinant Proteins Market by End User
12.5.1.6 UAE
12.5.1.6.1 UAE Recombinant Proteins Market by Product & Services
12.5.1.6.2 UAE Recombinant Proteins Market by Host Cell
12.5.1.6.3 UAE Recombinant Proteins Market by Application
12.5.1.6.4 UAE Recombinant Proteins Market by End User
12.5.1.7 Egypt
12.5.1.7.1 Egypt Recombinant Proteins Market by Product & Services
12.5.1.7.2 Egypt Recombinant Proteins Market by Host Cell
12.5.1.7.3 Egypt Recombinant Proteins Market by Application
12.5.1.7.4 Egypt Recombinant Proteins Market by End User
12.5.1.8 Saudi Arabia
12.5.1.8.1 Saudi Arabia Recombinant Proteins Market by Product & Services
12.5.1.8.2 Saudi Arabia Recombinant Proteins Market by Host Cell
12.5.1.8.3 Saudi Arabia Recombinant Proteins Market by Application
12.5.1.8.4 Saudi Arabia Recombinant Proteins Market by End User
12.5.1.9 Qatar
12.5.1.9.1 Qatar Recombinant Proteins Market by Product & Services
12.5.1.9.2 Qatar Recombinant Proteins Market by Host Cell
12.5.1.9.3 Qatar Recombinant Proteins Market by Application
12.5.1.9.4 Qatar Recombinant Proteins Market by End User
12.5.1.10 Rest of Middle East
12.5.1.10.1 Rest of Middle East Recombinant Proteins Market by Product & Services
12.5.1.10.2 Rest of Middle East Recombinant Proteins Market by Host Cell
12.5.1.10.3 Rest of Middle East Recombinant Proteins Market by Application
12.5.1.10.4 Rest of Middle East Recombinant Proteins Market by End User
12.5.2. Africa
12.5.2.1 Africa Recombinant Proteins Market by country
12.5.2.2 Africa Recombinant Proteins Market by Product & Services
12.5.2.3 Africa Recombinant Proteins Market by Host Cell
12.5.2.4 Africa Recombinant Proteins Market by Application
12.5.2.5 Africa Recombinant Proteins Market by End User
12.5.2.6 Nigeria
12.5.2.6.1 Nigeria Recombinant Proteins Market by Product & Services
12.5.2.6.2 Nigeria Recombinant Proteins Market by Host Cell
12.5.2.6.3 Nigeria Recombinant Proteins Market by Application
12.5.2.6.4 Nigeria Recombinant Proteins Market by End User
12.5.2.7 South Africa
12.5.2.7.1 South Africa Recombinant Proteins Market by Product & Services
12.5.2.7.2 South Africa Recombinant Proteins Market by Host Cell
12.5.2.7.3 South Africa Recombinant Proteins Market by Application
12.5.2.7.4 South Africa Recombinant Proteins Market by End User
12.5.2.8 Rest of Africa
12.5.2.8.1 Rest of Africa Recombinant Proteins Market by Product & Services
12.5.2.8.2 Rest of Africa Recombinant Proteins Market by Host Cell
12.5.2.8.3 Rest of Africa Recombinant Proteins Market by Application
12.5.2.8.4 Rest of Africa Recombinant Proteins Market by End User
12.6. Latin America
12.6.1 Latin America Recombinant Proteins Market by country
12.6.2 Latin America Recombinant Proteins Market by Product & Services
12.6.3 Latin America Recombinant Proteins Market by Host Cell
12.6.4 Latin America Recombinant Proteins Market by Application
12.6.5 Latin America Recombinant Proteins Market by End User
12.6.6 Brazil
12.6.6.1 Brazil Recombinant Proteins Market by Product & Services
12.6.6.2 Brazil Recombinant Proteins Market by Host Cell
12.6.6.3 Brazil Recombinant Proteins Market by Application
12.6.6.4 Brazil Recombinant Proteins Market by End User
12.6.7 Argentina
12.6.7.1 Argentina Recombinant Proteins Market by Product & Services
12.6.7.2 Argentina Recombinant Proteins Market by Host Cell
12.6.7.3 Argentina Recombinant Proteins Market by Application
12.6.7.4 Argentina Recombinant Proteins Market by End User
12.6.8 Colombia
12.6.8.1 Colombia Recombinant Proteins Market by Product & Services
12.6.8.2 Colombia Recombinant Proteins Market by Host Cell
12.6.8.3 Colombia Recombinant Proteins Market by Application
12.6.8.4 Colombia Recombinant Proteins Market by End User
12.6.9 Rest of Latin America
12.6.9.1 Rest of Latin America Recombinant Proteins Market by Product & Services
12.6.9.2 Rest of Latin America Recombinant Proteins Market by Host Cell
12.6.9.3 Rest of Latin America Recombinant Proteins Market by Application
12.6.9.4 Rest of Latin America Recombinant Proteins Market by End User
13 Company Profile
13.1 Thermo Fisher Scientific, Inc.
13.1.1 Company Overview
13.1.2 Financials
13.1.3 Product/ Services Offered
13.1.4 SWOT Analysis
13.1.5 The SNS View
13.2 Miltenyi Biotech
13.2.1 Company Overview
13.2.2 Financials
13.2.3 Product/ Services Offered
13.2.4 SWOT Analysis
13.2.5 The SNS View
13.3 Sino Biological Inc.
13.3.1 Company Overview
13.3.2 Financials
13.3.3 Product/ Services Offered
13.3.4 SWOT Analysis
13.3.5 The SNS View
13.4 Merck KGaA
13.4 Company Overview
13.4.2 Financials
13.4.3 Product/ Services Offered
13.4.4 SWOT Analysis
13.4.5 The SNS View
13.5 Abcam plc
13.5.1 Company Overview
13.5.2 Financials
13.5.3 Product/ Services Offered
13.5.4 SWOT Analysis
13.5.5 The SNS View
13.6 Biolegend
13.6.1 Company Overview
13.6.2 Financials
13.6.3 Product/ Services Offered
13.6.4 SWOT Analysis
13.6.5 The SNS View
13.7 Bio-Rad Laboratories, Inc.
13.7.1 Company Overview
13.7.2 Financials
13.7.3 Product/ Services Offered
13.7.4 SWOT Analysis
13.7.5 The SNS View
13.8 GenScript Biotech Corporation
13.8.1 Company Overview
13.8.2 Financials
13.8.3 Product/ Services Offered
13.8.4 SWOT Analysis
13.8.5 The SNS View
13.9 Enzo Life Sciences, Inc.
13.9.1 Company Overview
13.9.2 Financials
13.9.3 Product/ Services Offered
13.9.4 SWOT Analysis
13.9.5 The SNS View
13.10 Shenandoah Biotechnology Inc.
13.10.1 Company Overview
13.10.2 Financials
13.10.3 Product/ Services Offered
13.10.4 SWOT Analysis
13.10.5 The SNS View
13.11 BPS Bioscience, Inc.
13.11.1 Company Overview
13.11.2 Financials
13.11.3 Product/ Services Offered
13.11.4 SWOT Analysis
13.11.5 The SNS View
14. Competitive Landscape
14.1 Competitive Bench marking
14.2 Market Share Analysis
14.3 Recent Developments
14.3.1 Industry News
14.3.2 Company News
14.3.3 Mergers & Acquisitions
15. USE Cases and Best Practices
16. Conclusion
An accurate research report requires proper strategizing as well as implementation. There are multiple factors involved in the completion of good and accurate research report and selecting the best methodology to compete the research is the toughest part. Since the research reports we provide play a crucial role in any company’s decision-making process, therefore we at SNS Insider always believe that we should choose the best method which gives us results closer to reality. This allows us to reach at a stage wherein we can provide our clients best and accurate investment to output ratio.
Each report that we prepare takes a timeframe of 350-400 business hours for production. Starting from the selection of titles through a couple of in-depth brain storming session to the final QC process before uploading our titles on our website we dedicate around 350 working hours. The titles are selected based on their current market cap and the foreseen CAGR and growth.
The 5 steps process:
Step 1: Secondary Research:
Secondary Research or Desk Research is as the name suggests is a research process wherein, we collect data through the readily available information. In this process we use various paid and unpaid databases which our team has access to and gather data through the same. This includes examining of listed companies’ annual reports, Journals, SEC filling etc. Apart from this our team has access to various associations across the globe across different industries. Lastly, we have exchange relationships with various university as well as individual libraries.
Step 2: Primary Research
When we talk about primary research, it is a type of study in which the researchers collect relevant data samples directly, rather than relying on previously collected data. This type of research is focused on gaining content specific facts that can be sued to solve specific problems. Since the collected data is fresh and first hand therefore it makes the study more accurate and genuine.
We at SNS Insider have divided Primary Research into 2 parts.
Part 1 wherein we interview the KOLs of major players as well as the upcoming ones across various geographic regions. This allows us to have their view over the market scenario and acts as an important tool to come closer to the accurate market numbers. As many as 45 paid and unpaid primary interviews are taken from both the demand and supply side of the industry to make sure we land at an accurate judgement and analysis of the market.
This step involves the triangulation of data wherein our team analyses the interview transcripts, online survey responses and observation of on filed participants. The below mentioned chart should give a better understanding of the part 1 of the primary interview.
Part 2: In this part of primary research the data collected via secondary research and the part 1 of the primary research is validated with the interviews from individual consultants and subject matter experts.
Consultants are those set of people who have at least 12 years of experience and expertise within the industry whereas Subject Matter Experts are those with at least 15 years of experience behind their back within the same space. The data with the help of two main processes i.e., FGDs (Focused Group Discussions) and IDs (Individual Discussions). This gives us a 3rd party nonbiased primary view of the market scenario making it a more dependable one while collation of the data pointers.
Step 3: Data Bank Validation
Once all the information is collected via primary and secondary sources, we run that information for data validation. At our intelligence centre our research heads track a lot of information related to the market which includes the quarterly reports, the daily stock prices, and other relevant information. Our data bank server gets updated every fortnight and that is how the information which we collected using our primary and secondary information is revalidated in real time.
Step 4: QA/QC Process
After all the data collection and validation our team does a final level of quality check and quality assurance to get rid of any unwanted or undesired mistakes. This might include but not limited to getting rid of the any typos, duplication of numbers or missing of any important information. The people involved in this process include technical content writers, research heads and graphics people. Once this process is completed the title gets uploader on our platform for our clients to read it.
Step 5: Final QC/QA Process:
This is the last process and comes when the client has ordered the study. In this process a final QA/QC is done before the study is emailed to the client. Since we believe in giving our clients a good experience of our research studies, therefore, to make sure that we do not lack at our end in any way humanly possible we do a final round of quality check and then dispatch the study to the client.
The Intensive Care Unit (ICU) Market size was valued at $ 3.10 Bn in 2022 and is expected to reach $ 9.45 Bn by 2030,and grow at CAGR of 14.5 % over the forecast period of 2023-2030.
The Proteomics Market size was estimated USD 25.3 billion in 2022 and is expected to reach USD 70.8 billion by 2030 at a CAGR of 13.7% during the forecast period of 2023-2030.
The Cell Dissociation Market size was estimated USD 311.8 million in 2022 and is expected to reach USD 864.7 million by 2030 at a CAGR of 13.6% during the forecast period of 2023-2030.
The Tissue Diagnostics Market Size was valued at USD 5.28 billion in 2022, and is expected to reach USD 8.61 billion by 2030 and grow at a CAGR of 6.3% over the forecast period 2023-2030.
The Ophthalmology PACS Market Size was esteemed at USD 143.83 million of every 2022, and is expected to arrive at USD 245.38 million by 2030, and develop at a CAGR of 6.9% over the gauge period 2023-2030.
The BOTOX Market size was estimated USD 7.22 billion in 2022 and is expected to reach USD 10.99 billion By 2030 at a CAGR of 5.4% during the forecast period of 2023-2030.
Hi! Click one of our member below to chat on Phone
© 2024 All Rights Reserved by SNS Insider Pvt Ltd
